My name is Barbara Sanders. I’m 65 years old and live in San Diego, California. Today I enjoy all America’s Finest City has to offer including long hikes year-round, reading on the beach and boating with friends. But life wasn’t … Read more
By Gene Emery
Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more
When I was a teenager, I found out that I had Polycystic ovary syndrome (PCOS). PCOS is a hormonal disorder that can cause cysts on the ovaries, and I would often feel when I had cysts, and when they would … Read more
Photo: Marina Baroff, MPH, FACHE, Senior Director, Service Innovation
firstname.lastname@example.org | www.stepsthrough.org
When I was first diagnosed with ovarian cancer, I made the decision to share my story, not because it was glamorous, but in the hope that I could save a life. In February of 2018, after missing my period, I
Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more
By Jessica Skarzynski
The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous … Read more
By Wayne Kuznar
The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more
A laboratory study published in Clinical Cancer Research offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.
The study is the first to show that the natural stiffening of the ovaries called fibrosis … Read more
We would love to hear from the Clearity Community – patients, caregivers, and loved ones – about your experiences on how you have been affected by ovarian cancer. Sharing your story is a way to promote awareness, connect with people … Read more
With so much information at your fingertips, we understand how difficult it can be to find trustworthy, lay friendly sources that are relevant to you and your specific ovarian cancer journey. The Clearity Foundation exists to help women find credible … Read more
By Charles Bankhead
Anti-folate fails phase III test, but key biomarker measurement may have been faulty.
An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more
By Pam Harrison
Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.
Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more
By Ed Susman
PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.
Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more
By Charles Bankhead
Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.
Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more
By Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance, and mortality remains high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer.
A new study in … Read more
By Thomas J. Pier, MSW, LCSW, OSW-C, CMF, and Marina Baroff, MPH, MA, FACHE
What if every woman with ovarian cancer had help setting a clear direction through the uncertain landscape of the diagnosis? Imagine these women having access to … Read more